ALAMEDA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.07) per share which beat the analyst c

All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-13

Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosi

Vivani Medical NASDAQ: VANI said it is preparing to begin human testing of its semaglutide implant i

ALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company

NPM-139, which utilizes Vivani’s NanoPortal™ platform technology, is under development for chronic w

ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or

Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani"), a clinical-stage biopharmaceutical company de

SALT LAKE CITY--(BUSINESS WIRE)--ClearOne, Inc. (Nasdaq: CLRO) (“ClearOne”) announced today that it

Vivani proposes to merge Cortigent, Inc. with a wholly owned subsidiary of ClearOne, Inc. (Nasdaq: C

ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or

Vivani CEO Adam Mendelsohn, Ph.D., stated, "HREC approval to initiate SLIM-1 in Australia marks

ALAMEDA, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or

Lake Street analyst Thomas Flaten initiates coverage on Vivani Medical (NASDAQ:VANI) with a Buy r

ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI ) (“Vivani” o

Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under develo

Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) Director Gregg Williams purchased 1,587,301 sh

Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) was the recipient of a significant increase in

Vivani Medical (NASDAQ: VANI - Get Free Report) and Verrica Pharmaceuticals (NASDAQ: VRCA - Get Free

Vivani Medical (VANI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.09) per share which beat the analyst c

Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept da

Vivani Medical (NASDAQ: VANI - Get Free Report) is projected to post its Q4 2025 results before the

Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) was the recipient of a significant decrease in

Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage bio

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst co

Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical

https://d1io3yog0oux5.cloudfront.net/_8b0e72ba9731939ad4ef3d445345826e/vivanimedical/db/2227/20875/p

Cortigent is a leading developer of brain implant devices based on precision neurostimulation techno

NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administrationFirs

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma

https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-ep

https://www.medscape.com/viewarticle/ada-advises-against-using-compounded-glp-1-ra-medications-2024a

https://www.statnews.com/2024/10/30/novo-nordisk-ozempic-wegovy-fda-available-or-in-shortage/

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarter

The Dow Jones index closed higher by over 300 points on Thursday. When insiders purchase or sell sha

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the co